ライフサイエンスコーパス: genital infection

1 solate lacked virulence in a murine model of genital infection.

2 properties, in a murine model of chlamydial genital infection.

3 erent time points throughout the course of a genital infection.

4 rotective immunity against murine chlamydial genital infection.

5 as tested by use of a murine model of female genital infection.

6 y slightly delayed resolution of the primary genital infection.

7 2 gB2 and gD2 in response to recurrent HSV-2 genital infection.

8 echanisms associated with protection against genital infection.

9 oduce protective immunity against chlamydial genital infection.

10 and CCR5-dependent migration observed during genital infection.

11 t Sigmodon hispidus model of HSV-2 and HSV-1 genital infection.

12 mplex virus type 1 (HSV-1) or type 2 (HSV-2) genital infection.

13 ot required for controlling chlamydial lower genital infection.

14 erity of oviduct pathology upon C. muridarum genital infection.

15 the host response in immunity to chlamydial genital infection.

16 response in the male urethra to a chlamydial genital infection.

17 influx or normal resolution of C. muridarum genital infection.

18 r to what has been found in rodent models of genital infection.

19 t trichomonal, gonococcal, and/or chlamydial genital infection.

20 f trichomonal, gonococcal, and/or chlamydial genital infection.

21 accine by using a murine model of chlamydial genital infection.

22 s of IL-1beta expression during a chlamydial genital infection.

23 chlamydial developmental cycle in an actual genital infection.

24 ount >10,000, or gonococcal/chlamydial lower genital infection.

25 llowing the resolution of primary chlamydial genital infection.

26 ction and excretion during murine chlamydial genital infection.

27 umoral immune responses during uncomplicated genital infections.

28 correlated with the occurrence of antenatal genital infections.

29 dial gastrointestinal infection than against genital infections.

30 ar human pathogen responsible for ocular and genital infections.

31 ccur in the absence of detectable viremia or genital infections.

32 ry effective vaccine against respiratory and genital infections.

33 gainst a variety of enteric, respiratory, or genital infections.

34 ns of patients with confirmed C. trachomatis genital infection: 40 women with pelvic inflammatory dis

35 pisodes (56.6% vs. 51.8%), events suggesting genital infection (9.0% vs. 2.5%), and events suggesting

36 erval: 0.42, 1.38) nor gonococcal/chlamydial genital infection (adjusted hazard ratio = 1.16, 95% con

37 ity against reinfection develops after human genital infection, although it appears, at best, to be p

38 e is known about the concurrence of oral and genital infection among healthy individuals.

39 development of PID or gonococcal/chlamydial genital infection among predominantly young, African-Ame

40 this study, we assessed the risk of incident genital infection and 6-month persistent genital infecti

41 This study shows that SIV genital infection and disease course are enhanced by sub

42 t viral vaccines in protection against HSV-2 genital infection and disease.

43 le of these cells in resolution of a primary genital infection and in protection of HSV-immune animal

44 acterize the influence of IRF3 on chlamydial genital infection and its relationship to IFN-beta expre

45 our understanding of immunity to chlamydial genital infection and may provide important insight into

46 lication-defective HSV vaccine against HSV-2 genital infection and that B7-1 and B7-2 induce immune r

47 Here we review immunity to chlamydial genital infection and vaccine development using the C. m

48 implemented to control Chlamydia trachomatis genital infections and their complications have shown in

49 and might increase risk of urinary tract and genital infection, and excessive inhibition of SGLT1 can

50 e of FLG mutations on the risk of AD flares, genital infections, and postpartum problems related to p

51 Joint Infections, Urinary Tract Infections, Genital Infections, and Skin and Soft Tissue Infections;

52 he pathologic consequences of C. trachomatis genital infection are well-established, the mechanism(s)

53 mpagliflozin, there was an increased rate of genital infection but no increase in other adverse event

54 Our results thus newly reveal that genital infection by an obligate intracellular bacterium

55 herefore, it is possible that women cured of genital infection by antibiotics remain infected in the

56 FI) represents 36% of female infertility and genital infection by Chlamydia trachomatis (C. trachomat

57 Genital infection by herpes simplex virus (HSV)-2 offers

58 mmunity is crucial for resistance of mice to genital infection by the obligate intracellular bacteriu

59 HPV) may affect risks of subsequent incident genital infections by HPV 6, 11, 16, or 18 in men.

60 In women, genital infection can cause endometritis and pelvic infl

61 Ascending genital infections cause inflammation of fallopian tubes

62 protection against the life-long, recurrent genital infections caused by HSV-2 have failed.

63 oteases, the caspases, during C. trachomatis genital infection causes the disruption of key fertility

64 bit delayed clearance of Chlamydia muridarum genital infection compared to wild-type (WT) mice.

65 ing hazard ratios (HRs) among men with prior genital infection, compared with men with no prior genit

66 low-level Chlamydia psittaci and C. pecorum genital infection detected in virgin heifers suggests pr

67 Aside from an increased risk of mycotic genital infections, empagliflozin-treated patients had f

68 s are being used to help differentiate lower genital infection from upper genital disorder.

69 n individual analyses, men with prior HPV 16 genital infections had a significantly higher risk of su

70 antibiotic intervention of human chlamydial genital infection has a similar effect on protective imm

71 rechallenge in a murine model of chlamydial genital infection has been achieved only by infection or

72 The murine model of C. muridarum genital infection has been extremely useful for identifi

73 tic evaluation of HSV viremia during primary genital infection has not been performed previously.

74 um and Chlamydia trachomatis mouse models of genital infection have been used to study chlamydial imm

75 obicide, is an effective suppressor of HSV-2 genital infection in female BALB/c mice.

76 solution of primary and secondary chlamydial genital infection in immunoglobulin A (IgA)-deficient (I

77 he course and outcome of Chlamydia muridarum genital infection in mice genetically deficient in the r

78 s essential for the resolution of chlamydial genital infection in mice.

79 known about the host response to chlamydial genital infection in the male, particularly about the na

80 oviduct pathology during Chlamydia muridarum genital infection in the mouse model.

81 A major problem in the study of chlamydial genital infections in animal models has been the use of

82 The majority of Chlamydia trachomatis genital infections in humans are asymptomatic and withou

83 r mechanistic models to longitudinal data on genital infections in unvaccinated men.

84 l infection, compared with men with no prior genital infection, in individual HPV type and grouped HP

85 Murine genital infection induced with the mouse pneumonitis bio

86 pigs acquired via sexual contact to those of genital infections induced artificially with known quant

87 Nine of 217 patients (4.1%) with genital infection/inflammation had objective ReA feature

88 Genital infection/inflammation was asymptomatic in 78% o

89 Chlamydia trachomatis genital infection is a worldwide public health problem,

90 the prevalence of human papillomavirus (HPV) genital infection is similarly high in males and females

91 nd disease severity of Chlamydia trachomatis genital infection is whether more prevalent strains or s

92 ution of herpes simplex virus type 2 (HSV-2) genital infections is not fully understood.

93 sponse associated with Chlamydia trachomatis genital infections is thought to be initiated by the rel

94 le of inflammasome components during in vivo genital infection, mice lacking NLRP3, NLRC4, and ASC we

95 Using the Chlamydia muridarum genital infection model of mice, which replicates many f

96 Our results indicate that primary genital infection of mice with murine C. trachomatis ind

97 dant stress, were elevated during chlamydial genital infection of mice.

98 Genital infection of rats with Mycoplasma pulmonis cause

99 cellular pathogen responsible for ocular and genital infections of significant public health importan

100 Nongonococcal genital infections, often asymptomatic, can trigger a re

101 erpes simplex virus type 2 (HSV-2) and other genital infections on human immunodeficiency virus type

102 revalent, asymptomatic Chlamydia trachomatis genital infection reduces reproductive sequelae in infec

103 nalyses showed consistent increased risks of genital infections (regulatory submissions 4.75 [4.00-5.

104 er; however, we propose that women, cured of genital infection, remain at risk for autoinoculation fr

105 bserved in women after Chlamydia trachomatis genital infection result from ascension of the bacteria

106 oral HPV infection was higher among men with genital infection than among uninfected men (11.4% vs. 5

107 OS2(-/-)) mice resolve Chlamydia trachomatis genital infection, the production of reactive nitrogen s

108 est that type I IFNs exacerbate C. muridarum genital infection through an inhibition of the chlamydia

109 ia trachomatis in an in vitro model of human genital infection using the intracellular iron-chelating

110 In genital infection, viral DNA reached SC and DRG simultan

111 ately preceding PID or gonococcal/chlamydial genital infection was not different between women who de

112 The proportion of patients with genital infections was greater with empagliflozin than p

113 r 1998, an outbreak of Chlamydia trachomatis genital infections was reported among 18 residents of a

114 Using the Chlamydia muridarum model of genital infection, we demonstrate a protective role for

115 ole of type I IFNs during in vivo chlamydial genital infection, we examined the course and outcome of

116 inoculating dose of C. muridarum modulates a genital infection, we measured innate and adaptive cell

117 ith possible or proven Chlamydia trachomatis genital infection were screened for symptoms of ReA.

118 en douching and PID or gonococcal/chlamydial genital infections were assessed by proportional hazards

119 m women with gonococcal cervicitis and other genital infections were examined.

120 s, symptoms, and other reports suggestive of genital infections were more frequent in the dapaglifloz

121 HSV-2 and other genital infections were the most important risk factors

122 Unlike the genital infection where CD8(+) T cells are primed, yet f

123 ment of a highly efficacious vaccine against genital infection will depend on the generation of a liv

124 (+) T cells, allowing for protection against genital infection with C. trachomatis.

125 es draining the genital tract in response to genital infection with C. trachomatis.

126 Genital infection with Chlamydia trachomatis results in

127 A-A*0201 transgenic mice following ocular or genital infection with either HSV-1 or HSV-2.

128 Genital infection with herpes simplex virus 2 (HSV-2) is

129 ent genital infection and 6-month persistent genital infection with HPV16 in relation to baseline ser

130 cing establishment of latent infection after genital infection with HSV-2.

131 Genital infection with human papillomavirus (HPV), as de

132 al studies from sub-Saharan Africa show that genital infection with Schistosoma haematobium [correcte

133 w cytometry the mononuclear cell response to genital infection with the agent of guinea pig inclusion

134 ular adhesion molecule type 1 (ICAM-1) after genital infection with the C. trachomatis agent of mouse

135 Genital infection with the inflammation- and caspase-ind

136 Following resolution of genital infection with the mouse pneumonitis (MoPn) biov

137 The molecular mechanisms of resistance to genital infection with the mouse pneumonitis (MoPn) stra

138 d chlamydial vaccine or repeated abbreviated genital infection with virulent chlamydiae promotes anam

139 abdominal pain are frequent complications of genital infections with Chlamydia trachomatis.

140 Genital infections with human papillomavirus (HPV) are i

141 1 (Th1) response is essential for resolving genital infections with the mouse pneumonitis biovar of